Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1126848-34-7 | MDL No. : | MFCD09027766 |
Formula : | C7H4BrNO | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | WPERWOJBMXTKKG-UHFFFAOYSA-N |
M.W : | 198.02 | Pubchem ID : | 55254617 |
Synonyms : |
|
Num. heavy atoms : | 10 |
Num. arom. heavy atoms : | 9 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 41.71 |
TPSA : | 26.03 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.8 cm/s |
Log Po/w (iLOGP) : | 2.05 |
Log Po/w (XLOGP3) : | 2.4 |
Log Po/w (WLOGP) : | 2.59 |
Log Po/w (MLOGP) : | 1.88 |
Log Po/w (SILICOS-IT) : | 2.62 |
Consensus Log Po/w : | 2.31 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -3.25 |
Solubility : | 0.112 mg/ml ; 0.000568 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.59 |
Solubility : | 0.511 mg/ml ; 0.00258 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -3.77 |
Solubility : | 0.0336 mg/ml ; 0.000169 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.55 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H332-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
71% | With sodium carbonate at 20℃; for 0.5h; regioselective reaction; | 2. Typical procedure of cyclization General procedure: A reaction tube (15 mL) equipped with a magnetic stirrer bar was charged with benzo[d]isoxazole (0.1 mmol), N-(benzyloxy)-2-bromo-2-methylpropanamide (0.2 mmol), Na2CO3 (0.4 mmol) in HFIP (1 mL). The reaction mixture was stirred at room temperature for 0.5 h. When the reaction was completed (as judged by thin layer chromatographic analysis), the mixture was diluted with ethyl acetate. The crude material was then filtered through Celite and thoroughly washed with ethyl acetate. The filtrate was then concentrated under rotary evaporation and then purified by column chromatography on silica gel (Petroleum/EtOAc = 20:1). |
[ 66033-69-0 ]
6-Bromo-3-methylbenzo[d]isoxazole
Similarity: 0.90
[ 796969-15-8 ]
4-Bromobenzo[d]isoxazol-3-amine
Similarity: 0.84
[ 177995-39-0 ]
6-Bromobenzo[d]isoxazol-3-amine
Similarity: 0.80
[ 66033-69-0 ]
6-Bromo-3-methylbenzo[d]isoxazole
Similarity: 0.90
[ 796969-15-8 ]
4-Bromobenzo[d]isoxazol-3-amine
Similarity: 0.84
[ 177995-39-0 ]
6-Bromobenzo[d]isoxazol-3-amine
Similarity: 0.80